Absolute and Comparative Subcutaneous Bioavailability of Ardeparin Sodium, a Low Molecular Weight Heparin

Summary

Ardeparin sodium (Normiflo®, Wyeth-Ayerst) is a low molecular weight heparin undergoing clinical evaluation as an antithrombotic agent. The objective of this study was to evaluate the absolute and comparative bioavailability of ardeparin following subcutaneous administration of three different formulations [two formulations of ardeparin at 10,000 anti-factor Xa (aXa) U/ml, but with different preservatives, and a 20,000 aXa U/ml formulation]. The study was conducted using a randomized 4-period crossover design (three subcutaneous treatments and one intravenous treatment) in 24 healthy subjects, and the pharmacokinetics of ardeparin were characterized by plasma anti-factor Ila (alia) and anti-factor Xa (aXa) activities. The mean absolute bioavailability of ardeparin based on alia activity ranged from 62% to 64% and the mean absolute bioavailability based on aXa activity ranged from 88% to 97%. Based on bioequivalence testing criteria, the three ardeparin formulations were bioequivalent.

• References

• 1 Rosenberg RD. Heparin-antithrombin system. In: Hemostasis and Thrombosis. Colman RW, Hirsh J, Marder V, Salzman EW. (eds). JB Lippincott; Philadelphia: 1983. pp 962-985
• 2 Harenberg J, Gnasso A, de VriesJX, Zimmermann R, Augustin J. Anticoagulant and lipolytic effects of a low molecular weight heparin fraction. ThrombRes 1985; 39: 683-692
• 3 Harenberg J, Gnasso A, de VriesJX, Zimmermann R, Augustin J. Inhibition of low molecular weight heparin by protamine chloride in vivo. ThrombRes 1985; 38: 11-20
• 4 Ozawa T, Mammen EF. LMW heparin (anti-Xa) assays for clinical monitoring and pharmacokinetic studies on the automated coagulation laboratory (ACL). Thromb Res 1992; 66: 287-298
• 5 Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71: 300-304
• 6 Ozawa T, Domagalski J, Mammen EF. Determination of low-molecular weight heparin by Heptest on the automated coagulation laboratory system. Am J Clin Pathol 1993; 99: 157-162
• 7 Jusko WJ. Guidelines for collection and analysis of pharmacokinetic data. In: Applied Pharmacokinetics. Evans W, Schentag JJ, Jusko WJ. (eds). Academic Press; Spokane: 1986
• 8 Gibaldi M, Perrier D. Pharmacokinetics. 2nded. Marcel Dekker; New York: 1986
• 9 Metzler CM, Elfring GL, McEwan AJ. A package of computer programs for pharmacokinetic modeling. Biometrics 1974; 30: 562-563
• 10 SAS Institute, Inc. SAS User’s Guide: Statistics. SAS Institute, Inc., Cary 1985
• 11 Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-680
• 12 Winjnand HP, Timmer CJ. Mini-computer programs for bioequivalence testing of pharmaceutical drug formulations in two-way cross-over studies. Comput Prog Biomed 1983; 17: 73-88
• 13 Kandtrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992; 22: 359-374
• 14 Harenberg J, Wurzner B, Zimmermann R, Schettler G. Bioavailability and antagonization of the low molecular weight heparin CY 216 in man. Thromb Res 1986; 44: 549-554
• 15 Bratt G, Tomebohm E, Widlund L, Lockner D. Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986; 42: 613-620
• 16 Emanuele RM, Fareed J. The effect of molecular weight on the bioavailability of heparin. Thromb Res 1987; 48: 591-596
• 17 Pedersen PC, Ostergaard PB, Hedner U, Bergqvist D, Matzsch T. Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. Thromb Res 1991; 61: 477-487
• 18 Frydman AM, Bara L, Le RouxY, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988; 28: 609-618
• 19 Dawes J, Bara L, Billaud E, Samama M. Relationship between biological activity and concentration of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis 1986; 16: 116-122
• 20 Bjork I, Olson ST, Shore JD. Molecular mechanisms of the accelerating effect of heparin on the reactions between antithrombin and clotting pro-teinases. In: Heparin. Lane DA, Lindahl IU. (eds). CRC Press; Boca Raton: 1989. pp 229-255
• 21 Simonneau G, Bergmann JF, Kher A, Soria C, Tobelem G. Pharmacokinetics of a low molecular weight heparin (Fragmin®) in young and elderly subjects. Thromb Res 1992; 66: 603-607
• 22 Bjomsson TD, Lagergren H, Ek S. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther 1982; 31: 104-113
• 23 Troy S, Fruncillo R, Ozawa T, Mammen E, Holloway S, Chiang S. The dose proportionality of the pharmacokinetics of ardeparin, a low molecular weight heparin, in healthy volunteers. J Clin Pharmacol 1995; 35: 1194-1199
• 24 Kristensen HI, Ostergaard PB, Nordfang O, Abildgaard U, Lindahl AK. Effect of tissue factor pathway inhibitor (TFPI) in the HEPTEST® assay and in an amidolytic anti factor Xa assay for LMW heparin. Thromb Haemost 1992; 68: 310-314
• 25 Hoppensteadt DA, Walenga JM, Fasanella A, Jeske W, Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 1995; 77: 175-185